12 Month Price Forecast For DYN
Distance to DYN Price Forecasts
DYN Price Momentum
๐ค Considering Dyne Therapeutics (DYN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 1:49 PM UTC
DYN Analyst Ratings & Price Targets
Based on our analysis of 12 Wall Street analysts, DYN has a bullish consensus with a median price target of $50.00 (ranging from $18.00 to $66.00). Currently trading at $13.91, the median forecast implies a 259.5% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Matteis at Stifel, projecting a 374.5% upside. Conversely, the most conservative target is provided by Tessa Romero at JP Morgan, suggesting a 29.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DYN Analyst Consensus
DYN Price Target Range
Latest DYN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DYN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 24, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $0.00 |
Jan 14, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $45.00 |
Jan 13, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $55.00 |
Jan 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $55.00 |
Jan 10, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $50.00 |
Dec 13, 2024 | Baird | Outperform | Initiates | $0.00 | |
Nov 26, 2024 | RBC Capital | Luca Issi | Outperform | Initiates | $45.00 |
Nov 13, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $50.00 |
Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $55.00 |
Oct 24, 2024 | JP Morgan | Tessa Romero | Neutral | Downgrade | $35.00 |
Sep 23, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $53.00 |
Sep 4, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $55.00 |
Sep 3, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $55.00 |
Aug 16, 2024 | Stifel | Paul Matteis | Buy | Maintains | $66.00 |
Aug 15, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $50.00 |
Aug 14, 2024 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $52.00 |
Aug 13, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $53.00 |
Aug 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $55.00 |
Jul 9, 2024 | JP Morgan | Tessa Romero | Overweight | Maintains | $43.00 |
May 21, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $42.00 |
Stocks Similar to Dyne Therapeutics Inc
The following stocks are similar to Dyne Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Dyne Therapeutics Inc (DYN) Financial Data
Dyne Therapeutics Inc has a market capitalization of $1.42B with a P/E ratio of -3.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Dyne Therapeutics Inc (DYN) Company Overview
About Dyne Therapeutics Inc
Develops therapeutics for muscle diseases.
The company operates as a biotechnology firm, focusing on developing a portfolio of therapeutics specifically for genetically driven muscle diseases. It generates revenue by advancing its clinical programs and potentially monetizing its therapeutic developments through partnerships, licensing agreements, or product sales once they receive regulatory approval.
Dyne Therapeutics utilizes its proprietary FORCE platform to deliver disease-modifying therapeutics aimed at conditions like myotonic dystrophy type 1 and Duchenne muscular dystrophy. Founded in 2017 and based in Waltham, Massachusetts, the company is positioned in a niche market with significant unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
173
CEO
Mr. John G. Cox M.B.A.
Country
United States
IPO Year
1993
Website
www.dyne-tx.comDyne Therapeutics Inc (DYN) Latest News & Analysis
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
12 days agoDyne Therapeutics (Nasdaq: DYN) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. ET.
Dyne Therapeutics' presentation at a major healthcare conference could signal advancements in their drug development, potentially influencing stock performance and investor sentiment in the biotech sector.
The Zacks Medical-Drugs industry is experiencing peak innovation, with CORT, AMRX, DYN, NKTR, and CRDL suggested as potential portfolio additions.
Innovation in the Zacks Medical-Drugs industry indicates potential growth and profitability for companies like CORT, AMRX, DYN, NKTR, and CRDL, which may enhance investment portfolios.
Dyne Therapeutics (DYN) is now technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates higher, indicating a potential trend reversal.
Dyne Therapeutics' oversold status and analysts' upgraded earnings estimates suggest a potential rebound, signaling a favorable buying opportunity for investors.
Dyne Therapeutics, Inc. plans to submit for U.S. Accelerated Approval in the first half of 2026.
Dyne Therapeutics' plan for U.S. Accelerated Approval signals potential for expedited market access and revenue growth, impacting stock performance and investor sentiment.
Dyne Therapeutics, Inc. (DYN) announced new data from its Phase 1/2 ACHIEVE trial of DYNE-101 for myotonic dystrophy type 1 (DM1) on Friday.
New trial data from Dyne Therapeutics on DYNE-101 could impact its stock performance and future funding, influencing investor sentiment and potential market opportunities in gene therapy.
Dyne plans to start a global expansion cohort of the ACHIEVE trial for DYNE-101 in DM1, aiming for U.S. Accelerated Approval submission in H1 2026 after positive study results.
The initiation of a global Registrational Expansion Cohort for DYNE-101 indicates potential regulatory approval and market entry, which could significantly impact Dyne Therapeutics' stock value and future revenues.
Frequently Asked Questions About DYN Stock
What is Dyne Therapeutics Inc's (DYN) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Dyne Therapeutics Inc (DYN) has a median price target of $50.00. The highest price target is $66.00 and the lowest is $18.00.
Is DYN stock a good investment in 2025?
According to current analyst ratings, DYN has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DYN stock?
Wall Street analysts predict DYN stock could reach $50.00 in the next 12 months. This represents a 259.5% increase from the current price of $13.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dyne Therapeutics Inc's business model?
The company operates as a biotechnology firm, focusing on developing a portfolio of therapeutics specifically for genetically driven muscle diseases. It generates revenue by advancing its clinical programs and potentially monetizing its therapeutic developments through partnerships, licensing agreements, or product sales once they receive regulatory approval.
What is the highest forecasted price for DYN Dyne Therapeutics Inc?
The highest price target for DYN is $66.00 from Paul Matteis at Stifel, which represents a 374.5% increase from the current price of $13.91.
What is the lowest forecasted price for DYN Dyne Therapeutics Inc?
The lowest price target for DYN is $18.00 from Tessa Romero at JP Morgan, which represents a 29.4% increase from the current price of $13.91.
What is the overall DYN consensus from analysts for Dyne Therapeutics Inc?
The overall analyst consensus for DYN is bullish. Out of 12 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $50.00.
How accurate are DYN stock price projections?
Stock price projections, including those for Dyne Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.